



Sun Pharmaceutical Industries Limited

Registered Office: SPARC, Tandajja, Vadodara – 390012, Gujarat, India.
Corporate Office: Sun House, Plot No. 201 B/1, Western Express Highway,
Goregaon (East), Mumbai - 400063, Maharashtra, India.
Tel: 022-43244324 | CIN: L24230GJ1993PLC019050
Website: www.sunpharma.com | Email Id: secretarial@sunpharma.com

NOTICE OF POSTAL BALLOT/E-VOTING

Timeline

| | |
|-------------------------------|--|
| E-Voting Begins | Monday, 24 February 2025 at 09:00 A.M. |
| E-Voting Ends | Tuesday, 25 March 2025 at 05.00 P.M. |
| Announcement of Voting Result | On or before Thursday, 27 March 2025 |

| Sl. No. | Particulars of Resolutions | Type of Resolution |
|---------|--|--------------------|
| 1. | Approval for Material Related Party Transactions between Taro Pharmaceuticals Inc., Canada and Sun Pharmaceutical Industries Inc., USA | Ordinary |
| 2. | Approval for Material Related Party Transactions between Taro Pharmaceutical Industries Ltd., Israel and Sun Pharmaceutical Industries Inc., USA | Ordinary |
| 3. | Approval for Material Related Party Transactions between Taro Pharmaceuticals U.S.A., Inc., USA and Sun Pharmaceutical Industries Inc., USA | Ordinary |

Index

| Sl. No. | Section | Page No. |
|---------|--|----------|
| 1. | Notice of Postal Ballot/E-voting | 2 |
| 2. | Explanatory Statement | 4 |
| 3. | Statutory Notes | 9 |
| 4. | Procedure for E-voting | 10 |

The Notice of the Postal Ballot/E-voting and Explanatory Statement is prepared pursuant to the applicable provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

NOTICE OF POSTAL BALLOT/E-VOTING

[Pursuant to Section 110 of the Companies Act, 2013, read with Rule 20 and 22 of the Companies (Management and Administration) Rules, 2014]

NOTICE is hereby given that the resolutions as set out below are proposed to be passed by the shareholders of Sun Pharmaceutical Industries Limited (“the Company”/“Sun Pharma”) by way of Postal Ballot/ E-voting (“Notice”), pursuant to the applicable provisions¹ of the Companies Act, 2013 (“Act”), including the Secretarial Standards and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), as amended from time to time.

Item No. 1: Approval for Material Related Party Transactions between Taro Pharmaceuticals Inc., Canada and Sun Pharmaceutical Industries Inc., USA

To consider and, if thought fit, to pass the following resolution as an **Ordinary Resolution**:

“RESOLVED THAT pursuant to Regulation 23(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the approval of the shareholders of the Company be and is hereby accorded for material related party transactions involving funding by way of granting loan, giving guarantee, providing security or any other manner including earning interest thereon; and revenue from contracts with customer (purchase and sale of pharmaceutical products), reimbursements received, reimbursements paid, availing or rendering of services, to be entered into between Taro Pharmaceuticals Inc., Canada (“Taro Canada”) and Sun Pharmaceutical Industries Inc., USA (“SPI Inc.”), subsidiaries of the Company, for an aggregate amount not exceeding USD 890 million (equivalent to INR 76,763 million approximately) for the financial year 2025-26.

RESOLVED FURTHER THAT the Directors of the Company and Key Managerial Personnel be and are hereby severally authorised to do all such acts, deeds, matters and things as it may deem fit and settle all such issues, questions, difficulties or doubts whatsoever that may arise and to take all such decisions as may be required to give effect to this resolution.”

Please [click here](#) for the Explanatory Statement.

Item No. 2: Approval for Material Related Party Transactions between Taro Pharmaceutical Industries Ltd., Israel and Sun Pharmaceutical Industries Inc., USA

To consider and, if thought fit, to pass the following resolution as an **Ordinary Resolution**:

“RESOLVED THAT pursuant to Regulation 23(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the approval of the shareholders of the Company be and is hereby accorded for material related party transactions involving revenue from contracts with customers (purchase and sale of pharmaceutical products), reimbursements received, reimbursements paid, availing or rendering of services to be entered into between Taro Pharmaceutical Industries Ltd., Israel (“Taro Israel”) and Sun Pharmaceutical Industries Inc., USA (“SPI Inc.”), subsidiaries of the Company, for an aggregate amount not exceeding USD 180 million (equivalent to INR 15,525 million approximately) for the financial year 2025-26.

RESOLVED FURTHER THAT the Directors of the Company and Key Managerial Personnel be and are hereby severally authorised to do all such acts, deeds, matters and things as it may deem fit and settle all such issues, questions, difficulties or doubts whatsoever that may arise and to take all such decisions as may be required to give effect to this resolution.”

Please [click here](#) for the Explanatory Statement.

¹ Section 108 and 110 of the Companies Act, 2013 (“the Act”), read with Rule 20 and Rule 22 of the Companies (Management and Administration) Rules, 2014 (“Rules”), of the Act and the Rules and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Secretarial Standards-2 issued by the Institute of Company Secretaries of India.

Item No. 3: Approval for Material Related Party Transactions between Taro Pharmaceuticals U.S.A., Inc., USA and Sun Pharmaceutical Industries Inc., USA

To consider and, if thought fit, to pass the following resolution as an **Ordinary Resolution**:

“RESOLVED THAT pursuant to Regulation 23(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the approval of the shareholders of the Company be and is hereby accorded for material related party transactions involving business transfer (including transfer of inventory, reimbursement of expenses and allied activities) to be entered into between Taro Pharmaceuticals U.S.A., Inc. USA (“TARO Pharma USA”) and Sun Pharmaceutical Industries Inc., USA (“SPI Inc.”), subsidiaries of the Company, for an aggregate amount not exceeding USD 225 million (equivalent to INR 19,407 million approximately) for the financial year 2025-26.

RESOLVED FURTHER THAT the Directors of the Company and Key Managerial Personnel be and are hereby severally authorised to do all such acts, deeds, matters and things as it may deem fit and settle all such issues, questions, difficulties or doubts whatsoever that may arise and to take all such decisions as may be required to give effect to this resolution.”

Please [click here](#) for the Explanatory Statement.

Please [click here](#) for the Index

**EXPLANATORY STATEMENT
FOR ITEM NOS 1, 2 AND 3**

[Pursuant to Section 102 of the Companies Act, 2013]

Regulatory Background

According to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, related party transactions encompass dealings between the listed entity or its subsidiaries and their related parties. A material-related party transaction is defined as any transaction, whether considered individually or in conjunction with prior transactions within a financial year, exceeding INR 1,000 Crore/INR 10,000 million or ten per cent of the annual consolidated turnover as per the last audited financial statements of the listed entity, whichever is lower. The material related party transactions require prior approval from the shareholders.

Details of the Transactions

Taro Pharmaceutical Industries Ltd., Israel (“Taro Israel”), a 78.48% subsidiary company, was listed on the NYSE. In June 2024, Sun Pharma acquired the remaining 21.52% stake, leading to 100% ownership in Taro Israel. Sun Pharma holds Taro Israel through Alkaloida Chemical Company Zrt., Hungary, a 99.99% subsidiary company. Therefore, even after acquiring 100% ownership, Taro Israel and its subsidiaries are not wholly owned subsidiaries of Sun Pharma.

After the complete acquisition of Taro Israel, various integration initiatives are being undertaken within the group, which will result in multiple material related party transactions. These transactions are considered at Item Nos. 1, 2, and 3 of the Notice. [Annexure A](#) provides all the relevant information, including the information required to be disclosed as per the SEBI master circular dated 11 November 2024.

The Audit Committee has reviewed the transactions in detail, and the Independent Directors on the Committee have approved them. The transactions are in the best interest of the Company. Therefore, based on the Audit Committee’s recommendations, the Board recommends the resolutions set out in Item Nos. 1, 2, and 3 for approval of the shareholders by way of Ordinary Resolutions.

None of the Company’s Directors or Key Managerial Personnel and their relatives, except Mr. Sudhir Valia, who is a Director of Taro Canada, Taro Pharma USA, and SPI Inc., and Mr. Gautam Doshi, an Independent Director who is also a Director of Taro Pharma USA and SPI Inc., are in any way concerned or interested in the resolutions.

DISCLOSURE OF INFORMATION ON THE PROPOSED TRANSACTIONS

| Sl. No. | Description | Item No. 1 | Item No. 2 | Item No. 3 |
|---------|---|--|--|--|
| a. | Name of the related party and its relationship with the listed entity or its subsidiary, including the nature of its concern or interest (financial or otherwise) | Taro Pharmaceuticals Inc., Canada (“TARO Canada”), a 99.99% Subsidiary and Sun Pharmaceutical Industries Inc. (“SPI Inc.”), a Wholly-owned Subsidiary Sun Pharmaceutical Industries Limited (“Sun Pharma”) is not a party to the proposed related-party transaction. | Taro Pharmaceutical Industries Ltd. Israel (“Taro Israel”), a 99.99% Subsidiary and Sun Pharmaceutical Industries Inc. (SPI Inc.), a Wholly-owned Subsidiary Sun Pharma is not a party to the proposed related-party transaction. | Taro Pharmaceuticals U.S.A., Inc. USA (“TARO Pharma USA”), a 99.99% Subsidiary and Sun Pharmaceutical Industries Inc., USA (“SPI Inc.”), a Wholly-owned Subsidiary Sun Pharma is not a party to the proposed related-party transaction. |
| b. | Type, material terms and particulars of the proposed transaction | 1. Funding by granting loan, giving guarantee, providing security or any other manner, including earning interest thereon 2. Revenue from contracts with customers (purchase and sale of pharmaceutical products), reimbursements received, reimbursements paid, availing or rendering of services | Revenue from contracts with customers (purchase and sale of pharmaceutical products), reimbursements received, reimbursements paid, availing or rendering of services | Business transfer (including transfer of inventory, reimbursement of expenses and allied activities) |
| c. | Tenure of the proposed transaction (particular tenure shall be specified) | FY 2025-26 | FY 2025-26 | FY 2025-26 |
| d. | Value of the proposed transaction | 1. Funding by granting loan, giving guarantee, providing security, or in any other manner, including earning interest thereon - USD 650 million (equivalent to INR 56,063 million approx.) 2. Revenue from contracts with customers (purchase and sale of pharmaceutical products), reimbursements received, reimbursements paid, availing or | USD 180 million (equivalent to INR 15,525 million approx..) | USD 225 million (equivalent to INR 19,407 million approximately) |

| Sl. No. | Description | Item No. 1 | Item No. 2 | Item No. 3 |
|---------|--|--|---|---|
| | | rendering of services - USD 240 million (equivalent of INR 20,700 million approx.) | | |
| e. | The percentage of the listed entity's annual consolidated turnover for the immediately preceding financial year that is represented by the value of the proposed transaction (and for a RPT involving a subsidiary, such percentage is calculated on the basis of the subsidiary's annual turnover on a standalone basis shall be additionally provided) | For Sun Pharma – 15.8 % For Taro Canada – 294.2 % For SPI Inc – 66.8 % | For Sun Pharma – 3.2 % For Taro Israel – 97.9 % For SPI Inc – 13.5 % | For Sun Pharma – 4.0 % For Taro Pharma USA – 70.2 % For SPI Inc – 16.9 % |
| f. | Any advance paid or received for the contract or arrangement, if any | Not Applicable | Not Applicable | Not Applicable |
| g. | The manner of determining the pricing and other commercial terms, both included as part of the contract and not considered as part of the contract | On an arm's length basis and as per the applicable pricing guidelines pursuant to applicable local laws in the respective jurisdiction. | On an arm's length basis and as per the applicable pricing guidelines pursuant to applicable local laws in the respective jurisdiction. | On an arm's length basis and as per the applicable pricing guidelines pursuant to applicable local laws in the respective jurisdiction. |
| h. | Whether all factors relevant to the contract have been considered, if not, the details of factors not considered with the rationale for not considering those factors | Yes | Yes | Yes |
| i. | Name of the director or key managerial personnel who is related, if any. | Mr. Sudhir Valia, Director of the Company, is also the Director of Taro Canada and SPI Inc. Mr. Gautam Doshi, Director of the Company, is also a Director of SPI Inc. | Mr. Sudhir Valia and Mr. Gautam Doshi, Directors of the Company, are also Directors of SPI Inc. | Mr. Gautam Doshi, Director of the Company, is also a Director of SPI Inc. and Taro Pharma USA. Mr. Sudhir Valia, the company's Director, is also a Director of SPI Inc. and Taro Pharma USA. |
| j. | Justification as to why the RPT is in the interest of the listed entity. | As a part of global treasury operations, advances/loans/securities and guarantees are extended to and amongst the subsidiaries, which utilise | SPI Inc. shall act as the distributor of Taro Israel in the USA market. It will be guaranteed an arm's length remuneration for its distribution and ancillary activities. | As part of the group integration initiative, Taro Pharma USA's distribution business will be transferred to SPI Inc. |

| Sl. No. | Description | Item No. 1 | Item No. 2 | Item No. 3 |
|---------|--|---|----------------|----------------|
| | | <p>these funds for their general corporate purposes/working capital, etc.</p> <p>Further, SPI Inc. shall act as the distributor of Taro Canada in the USA market. SPI Inc. will be guaranteed an arm's length remuneration for its distribution and ancillary activities.</p> | | |
| k. | <p>If the transaction relates to any loans, inter-corporate deposits, advances or investments made or given by the listed entity or its subsidiary:</p> <p>i) details of the source of funds in connection with the proposed transaction</p> <p>ii) where any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments,</p> <ul style="list-style-type: none"> • nature of indebtedness; • cost of funds; and • tenure; <p>iii) applicable terms, including covenants, tenure, interest rate and repayment schedule, whether secured or unsecured; if secured, the nature of security,</p> <p>iv) the purpose for which the funds will be utilized by the ultimate beneficiary of such funds pursuant to the RPT</p> | <p>Internal accruals / own resources</p> <p>Not Applicable</p> <p>Funding by way of granting unsecured loans, from time to time, will be at such interest as per the applicable determined based on the applicable benchmark rates (SOFR + spread p.a.). The tenure of the loan provided from time to time shall be decided mutually within the overall time frame of 5 years.</p> <p>The purpose of the loan will be to meet the business funding requirements of SPI Inc.</p> | Not Applicable | Not Applicable |

| Sl. No. | Description | Item No. 1 | Item No. 2 | Item No. 3 |
|---------|---|-----------------------|-----------------------|-----------------------|
| l. | A statement that the valuation or other external party report, if any such report has been relied upon by the listed entity in relation to the proposed transaction will be made available through the registered email address of the shareholders | Not Applicable | Not Applicable | Not Applicable |
| m. | Percentage of the counter-party's annual consolidated turnover that is represented by the value of the proposed RPT on a voluntary basis | As per clause e above | As per clause e above | As per clause e above |
| n. | Any other information that may be relevant | - | - | - |

By order of the Board of Directors
For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No.: A23983

Place: Mumbai
Date: 20 February 2025

Please click [here](#) for Item No. 1, [here](#) for Item No. 2 and [here](#) for Item No. 3

Please [click here](#) for the Index.


STATUTORY NOTES

1. This Notice is being sent only in electronic form² to those shareholders whose e-mail addresses are registered with the Company/Registrar and Transfer Agent (“RTA”). Accordingly, a physical copy of the Notice is not being sent to the shareholders. The communication of the shareholders' assent or dissent would only take place through the remote E-voting system.
2. The Company has availed of services of Central Depository Services (India) Limited (“CDSL”) for this purpose. Shareholders are requested to read the instructions for Voting through electronic means/Procedure for E-voting by clicking [here](#).
3. This Notice and Explanatory Statement with requisite enclosure(s), have also been made available on the website of the Company i.e. www.sunpharma.com and on the website of the E-voting agency viz. Central Depository Services (India) Limited at <https://evoting.cdslindia.com>
4. Shareholders whose names appear on the Register of Members/List of Beneficial Owners as of **Monday, 17 February 2025** (‘Cut-off date’) will be entitled to cast their vote(s).
5. Voting can be exercised only by the shareholder or his/her duly constituted attorney or, in case of bodies corporate, the duly authorized person.
6. The voting rights of shareholders shall be in proportion to their shares of the paid-up equity share capital of the Company as on the Cut-off date fixed for the purpose.
7. The voting period begins on **Monday, 24 February 2025 at 09:00 A.M.** and ends on **Tuesday, 25 March 2025 at 05:00 P.M.** All dates and times mentioned herein are as per Indian Standard Time (“IST”). The E-voting module shall be disabled by CDSL for voting thereafter. During the E-voting Period, the shareholders may cast their e-vote remotely, by using the login method as applicable to them.
8. Mr. Chintan J. Goswami, Partner, M/s. KJB & Co. LLP, Mumbai, has been appointed as the scrutinizer for conducting the postal ballot process fairly and transparently.
9. After the electronic votes are scrutinized, the Scrutinizer will submit his report to the Chairman/ Company Secretary or any other authorised personnel of the Company. The voting results will be announced on or before **Thursday, 27 March 2025**. The said results shall be placed on the company’s website at www.sunpharma.com and simultaneously be intimated to the CDSL, National Stock Exchange of India Limited, and BSE Limited.
10. E-voting has been enabled for all demat account holders through a single login credential through their demat accounts/ websites of Depositories/ Depository Participants. Demat account holders can cast their vote without having to register again with the E-voting service providers, facilitating seamless authentication and enhancing the ease and convenience of participating in the E-voting process.
11. In terms of SEBI Circular on E-voting facility provided by listed companies, individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and e-mail ID in their demat accounts in order to access the E-voting facility.
12. The Registrar and Share Transfer Agents (RTA) of the Company is:
MUFG Intime India Private Limited, (Formerly Link Intime India Private Limited)
C-101, 247, L.B.S. Marg, Vikhroli (West), Mumbai – 400 083.
www.in.mpms.mufg.com
Tel: +91 22 4918 6270 / +91 22 4918 6000

Please [click here](#) for the Index.

² General Circular No. 09/2024 dated September 19, 2024 issued by Ministry of Corporate Affairs and SEBI circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2024/133 issued by SEBI on October 3, 2024.

PROCEDURE FOR E-VOTING



Individual Shareholders holding securities in Demat mode with CDSL

1. Users who use CDSL Easi or Easiest can log in with their existing user ID and password. They will find an option to access the e-voting page without needing more authentication. To log in, go to www.cdslindia.com, click on the Login icon, and select the New System Myeasi Tab.
2. After logging in successfully, Easi / Easiest users will see the e-voting option for companies that are currently eligible for e-voting. By clicking on this option, users can access the service provider's e-voting page to cast their votes during the remote voting period. There is also a link to go directly to the e-voting service provider's website, CDSL.
3. If you haven't registered for Easi or Easiest yet, go to www.cdslindia.com. Click on the Login icon, select the New System Myeasi Tab, and then choose the registration option.
4. Alternatively, users can access the e-voting page directly by entering their Demat Account Number and PAN via a link on the homepage of www.cdslindia.com. The system will confirm the user's identity by sending an OTP to the mobile and email registered in the Demat Account. After successful verification, users will see the available e-voting options and can connect to the e-voting Service Provider, CDSL.

Individual Shareholders holding securities in demat mode with NSDL

1. If you are registered for the NSDL IDeAS facility, go to the NSDL e-Services website. Open your web browser and type in this URL: <https://eservices.nsdl.com> on your computer or mobile device. When the e-Services home page appears, click on the “Beneficial Owner” icon found under the “Login” section in ‘IDeAS’. A new screen will show up where you need to enter your User ID and Password. Once you log in successfully, you can access e-voting services. Click on “Access to e-voting” to reach the e-voting page. Select the company name, Sun Pharmaceutical Industries Limited or the e-voting service provider name - CDSL, and you will be taken to the e-voting service provider's website to cast your vote during the remote e-voting period or to join the virtual meeting and vote.
2. If you're not yet registered for IDeAS e-Services, you can do so at <https://eservices.nsdl.com>. Select “Register Online for IDeAS” or go to <https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp>.
3. To use the NSDL e-voting system, go to the website by typing www.evoting.nsdl.com on your computer or mobile browser. When the homepage appears, click the “Login” icon in the ‘Shareholder/Member’ section. A new screen will show up. You will need to enter your User ID (your sixteen-digit demat account number with NSDL), your Password/OTP, and the Verification Code displayed. Once you log in successfully, you will be taken to the NSDL Depository site, where you can find the e-voting page. Click on Sun Pharmaceutical Industries Limited or the e-voting service provider, CDSL, to go to CDSL’s website to vote during remote e-voting.

Note: Shareholders who are unable to retrieve their User ID / Password are advised to use the Forget User ID and Forget Password options available at the website mentioned above.

Physical shareholders and Shareholders other than individual holding in demat form

1. Log on to the e-voting website - www.evotingindia.com
2. Click on the “Shareholders” module.
3. Now enter your User ID
 - a. For CDSL: 16 digits beneficiary ID
 - b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID
 - c. Shareholders holding shares in Physical Form should enter the Folio Number registered with the Company.
4. Next, enter the Image Verification as displayed and Click on Login

If a Demat account holder has logged on to www.evotingindia.com and voted on an earlier e-voting of any company, then your existing password will be used.

If a Demat account holder has forgotten the login password, enter the User ID and the image verification code, click on Forgot Password, and enter the details as prompted by the system.

If you are a first-time user, follow the steps given below:

| | |
|--|--|
| Option 1 - PAN | Enter your 10 digit alpha-numeric PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number/e-voting code sent by the Company/RTA or contact the Company/RTA. |
| Option 2 -Dividend Bank Details OR Date of Birth (DOB) | To log in, enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records. If both details are not recorded with the depository or company, please enter the member ID/folio number in the Dividend Bank details field as mentioned in Step 3 above. |

After entering these details appropriately, click on the “SUBMIT” tab.

Shareholders holding shares in physical form will then directly reach the Company’s selection screen. These login details can be used only for e-voting on the resolutions contained in this Notice. However, shareholders holding shares in demat form will now reach the ‘Password Creation’ menu, wherein they are required to enter their login password in the new password field.

1. Click on the **EVSN 250218011** for Sun Pharmaceutical Industries Limited.
2. On the voting page, you will see “RESOLUTION DESCRIPTION” and against the same, the option “YES/NO” for voting. Select the option YES or NO as desired. Option YES implies that you assent to the Resolution, and Option NO implies that you dissent from the Resolution.
3. Click on the “RESOLUTIONS FILE LINK” if you wish to view all the resolution details.
4. After selecting the resolution you have decided to vote on, click “SUBMIT”. A confirmation box will be displayed. If you wish to confirm your vote, click on “OK”; otherwise, to change your vote, click on “CANCEL” and modify your vote accordingly. You cannot modify your vote once you “CONFIRM” your vote on the resolution.

You can also take a print of the votes cast by clicking on the “Click here to print” option on the Voting page.

Additional instructions for non-individual shareholders and custodians

| | |
|----|--|
| 1. | Non-individual shareholders (i.e., other than Individuals, HUF, NRI, etc.) and Custodians are required to log on to www.evotingindia.com and register in the “Corporates” module. |
| 2. | A scanned copy of the registration form bearing the entity's stamp and signature should be emailed to helpdesk.evoting@cdslindia.com |
| 3. | After receiving the login details, a Compliance User should be created using the admin login and password. The Compliance User could link the account(s) for which they wish to vote. |
| 4. | The list of accounts linked in the login should be mailed to helpdesk.evoting@cdslindia.com . Once the accounts are approved, they will be able to cast their vote. |
| 5. | A scanned copy of the board resolution and power of attorney (POA) they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify. |
| 6. | Alternatively, non-individual shareholders are required to send the relevant board resolution/authority letter, etc., to the Scrutinizer and to the Company at the e-mail address secretarial@sunpharma.com if they have voted from the individual tab and not uploaded the same in the CDSL e-voting system for the Scrutinizer to verify. |

Helpdesk details

| | |
|---|---|
| Individual Shareholders holding securities in Demat mode with CDSL | Shareholders facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or call at toll free no.: 1800 2109911. |
| Individual Shareholders holding securities in Demat mode with NSDL | Shareholders facing any technical issue in login can contact the NSDL helpdesk by sending a request to evoting@nsdl.co.in or calling 022 4886 7000 and 022 2499 7000. |

If you have any questions or issues regarding attending Meetings and e-voting from the e-voting system, you may refer to the Frequently Asked Questions (“FAQs”) and e-voting manual available at www.evotingindia.com, under the “HELP” section.

All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Sr. Manager, (CDSL) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai-400013 or send an e-mail to helpdesk.evoting@cdslindia.com or call at toll free no.: 1800 2109911.

Please [click here](#) for the Index.
